Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREDMEN trial: intratympanic methylprednisolone vs placebo in Menière’s disease
2023-503340-13-00Phase 3Authorised
- Sponsor
- Leiden University Medical Center
- Start
- May 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Meniere Disease comparing Intratympanic methylprednisolone with Intratympanic placebo (sodium chloride 0.9%) (2 arms). Primary endpoint: Complete or substantial control of vertigo. Planned start May 2023; status: authorised.
02
Drugs
methylprednisolone
03
Conditions
Meniere Disease
Beyond the preview
Go deeper on 2023-503340-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503340-13-00.